Weight change and hormonal contraception: Fact and fiction

Expert Review of Obstetrics and Gynecology

Volumn 6, Issue 1, 2011, Pages 45-56

  Beksinska, Mags E ^a   Smit, Jenni A ^a   Guidozzi, Franco ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

adolescents; combination contraceptives; obesity; progestogen only contraceptives; side effects; weight; women

Indexed keywords

CONTRACEPTIVE AGENT; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ESTROGEN; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; PLACEBO;

ANTHROPOMETRY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FLUID RETENTION; HORMONAL CONTRACEPTION; HUMAN; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; NAUSEA; OBESITY; PERCEPTION; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 78650463829     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.77     Document Type: Review

References (79)

1. Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception 76, 208-214 (2007).
2. Vaughan B, Trussell J, Kosy K, Singh S, Jones R. Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family growth. Contraception 78, 271-283 (2008).
3. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-Acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone enanthate given in two dosage regimens and depot medroxyprogesterone acetate: final report. Contraception 23, 1-20 (1983).
4. Said S, Omar K, Koetsawang S et al. A multicentred Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 34(3), 223-235 (1986).
5. Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents reasons for and experience after discontinuation of the long-acting contraceptive Depo-Provera and Norplant. J. Adolesc. Health 19, 118-123 (1996).
6. Emans J, Grace E, Woods ER. Adolescents compliance with the use of oral contraceptives. J. Am. Med. Assoc. 257, 3377-3381 (1987).
7. Hamani Y, Sciaki-Tamir Y, Deri-Hasid R, Miller-Pogrund T, Milwidsky A, Haimov-Kochman R. Misconceptions about oral contraception pills among adolescents and physicians. Hum. Reprod. 22, 3078 3083 (2007).
8. Venkat P, Masch R, Ng E, Cremer M, Richman S, Arslan A. Knowledge and beliefs about contraception in urban Latina women. J. Community Health 33, 357-362 (2008).
9. Rosenburg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol. 179, 577-582 (1998).
10. Paul C, Skegg DCG, Williams S. Depo-medroxyprogesterone acetate: patterns of use and reasons for discontinuation. Contraception 56, 209-214 (1997).
11. Turner R. Most British women use reliable contraceptive methods, but many fear health risks from use. Fam. Plan. Persp. 26, 183-184 (1994).
12. Karlsson R, Linden A, Von Schultz B. Supression of 24 hour cholecystokinen secretion by oral contraceptives. Am. J. Obstet. Gynecol. 167, 58-59 (1992).
13. Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception 22, 605-622 (1980). 14 Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 4, CD003987 (2008).
14. Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta C. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception 64, 223-225 (2001).
15. Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception 62, 55-58 (2000).
16. Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when woman use depot-medroxyprogesterone acetate for contraception. Int. J. Obes. 29, 1252-1258 (2005).
17. Berenson MD, Rahman M. Changes in weight, total fat, percent boy fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am. J. Obstet. Gynecol. 200(93), 329.el-e8 (2009).
18. Mainwaring R, Hales HA, Stevenson K et al. Metabolic parameters, bleeding, and weight changes in US women using progestin-only contraceptives. Contraception 51, 149-153 (1995).
19. Le YL, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet. Gynecol. 114, 279-284 (2009).
20. Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am. J. Obstet. Gynecol. 114, 97-102 (1972).
21. Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, dos Santos Fernandes AM. Variations in body mass index of users of depot- medroxyprogesterone acetate as a contraceptive. Contraception 81, 107-111 (2010).
22. Rissir WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J. Adolesc. Health 24, 433-436 (1999).
23. Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J. Pediatr. Adolesc. Gynecol. 10, 18-23 (1997).
24. Bonny A, Britto M, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J. Pediatr. Adolesc. Gynecol. 17, 109-115 (2004).
25. Bonny AE, Ziegler J, Harvey R, Debanne S, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone acetate, oral contraceptive pills, or no hormonal contraceptive method. Arch. Pediatr. Adolesc. Med. 160, 40-45 (2006).
26. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J. Pediatr. Adolesc. Gynecol. 15, 79-82 (2002).
27. Beksinska ME, Kleinschmidt I, Smit JA, Milford C, Farley TMM. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, non users and discontinuers of contraception. Contraception 81(1), 30-34 (2010).
28. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception 52, 215-219 (1995).
29. Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception 58, 149-151 (1998).
30. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long term acceptors. Contraception 58, 149-151 (1998).
31. El Mahgoub S. Body weight and cycle control of injectable contraceptives. J. Reprod. Med. 24, 119-126 (1980).
32. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen- progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet. Gynecol. 103, 359-373 (2004).
33. Rosenberg M. Weight changes with COC use and during the menstrual cycle. Contraception 58, 345-349 (1998).
34. Coney P, Wasenik K, Langley RGB, Di Giovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception 63, 297-302 (2001).
35. Goldzeiher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil. Steril. 22, 609-623 (1971).
36. Gupta S. Weight gain on the combined pill - is it real? Hum. Reprod. Update 6, 427-431 (2000).
37. Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive Technology (19th revised edition). Ardent Media, NY, USA (2007).
38. World Health Organization Department of Reproductive Health and research (WHO/ RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communications Programs (CCP), INFO Project. Family Planning: a Global Handbook for Providers. CCP and WHO, Baltimore (MD, USA) and Geneva (Switzerland) (2007).
39. Westoff CF, Ryder NB. Duration of use of oral contraception in the United States, 1960-1965. Public Health Rep. 83(4), 277-287 (1968).
40. Bagshaw S. The combined oral contraceptive. Risks and adverse effects in perspective. Drug Saf. 12(2), 91-96 (1995).
41. Carpenter S, Neinstein LS. Weight gain in adolescent young adult COC users. J. Adolesc. Health Care 7(5), 342-344 (1986).
42. Neel EU, Litt IF, Jay MS. Side effects and compliance with low-and conventional-dose oral contraceptives among adolescents. J. Adolesc. Health Care 8(4), 327-329 (1987).
43. Khoo SK, Hacker N, Chang A. An incremental-dose combined oestrogen- progestogen oral contraceptive: effects on body weight, blood pressure, and biochemical parameters. Aust. N. Z. J. Obstet. Gynecol. 20(3), 172-176 (1980).
44. Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil. Steril. 63(3), 516-521 (1995).
45. Rapkin AJ. Yaz in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 53(9 Suppl.), 729-741 (2008).
46. Milsom I, Lete I, Bjertnaes A et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 'g ethinyl estradiol and 3 mg drospirenone. Hum. Reprod. 21, 2304-2311 (2006).
47. Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G. A comparative assessment of ORTHO EVRA TM/EVRA TM to placebo patch effects on body weight. Fertil. Steril. 76(Suppl. 1), 188 (2001).
48. Stewart FH, Kaunitz AM, La Guardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ ethinyl estradiol: a randomized trial. Obstet. Gynecol. 105, 1389-1396 (2005).
49. Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (ORTHO Evra/Evra). Fertil. Steril. 77(Suppl. 2), S19-S26 (2002).
50. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents-experience with the combined estrogen and progesting transdermal contraceptive method Ortho Evra. J. Pediatr. Adolesc. Gynecol. 18(2), 85-90 (2005).
51. Miller L, Verhoeven CHJ, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet. Gynecol. 3, 473-482 (2005).
52. Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, Nuva Ring®: an international study of user acceptability. Contraception 67, 187-194 (2003).
53. Roumen F, Apter D, Mulders T, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum. Reprod. 16, 469-475 (2001).
54. O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 72(5), 323-327 (2005).
55. Barreiros FA, Guazzelli CAF, Barbosa R, de Assis F, de Araujo FF. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception 81, 223-225 (2010).
56. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet. Gynecol. 100, 585-593 (2002).
57. Bahamondes L, Diaz J, Petta C, Hall P. Weight variation in users of the once-a-month injectable contraceptive Cyclofem. Adv. Contraception 14(4), 185-192 (1998).
58. Hassan EO, el-nahal N, el-Hussinie M. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Contraception 60(2), 87-92 (1999).
59. Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J. Reprod. Med. 41(5), 407-413 (1996).
60. Margulies R, Miller L. Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs. Contraception 63(3), 147-149 (2001).
61. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception 70, 269-275 (2004).
62. Westhoff C, Jain JK, Milsom I et al. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 ml. Contraception 75, 261-267 (2007).
63. Chaudhri R, Rizvi F, Afzal M. Body weight and bleeding pattern changes in woman using DMPA-SC. J. Coll. Physicians Surg. Pak. 19, 618-621 (2009).
64. Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception 80, 346-354 (2009).
65. Howard G, Blair M, Fotherby K, Elder MG, Bye P. Seven years clinical experience of the injectable contraceptive, norethisterone oenanthate. Br. J. Fam. Plann. 11, 9-16 (1985).
66. Glasier A. Implantable contraceptives for women: Effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 65, 29-37 (2002).
67. Glantz S, Glantz JC, Campbell-Heider N, Schaff E. Norplant use among urban minority women in the United States. Contraception 61(2), 83-90 (2000).
68. Sivin I, Alvarez F, Mishell DR et al. Contraception with two levenorgestrel rod implants: a 5-year study in the United States. Contraception 58, 275-282 (1998).
69. Berenson AB, Weimann CM, Rickens V. Contraceptive outcomes among adolescents prescribed Norplant implants vs COC after one year of use. Am. J. Obstet. Gynecol. 176, 586-592 (1997).
70. Kozlowski KJ, Rickert VI, Hendon A, Davis P. Adolescents and Norplant: preliminary findings of side effects. J. Adolesc. Health. 16, 373-378 (1995).
71. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international trials. Fertil. Steril. 91(5), 1646-1653 (2009).
72. Croxatto H, Urbancsek J, Massai R, Bennink HC, van Beek A; Implanon study group. A multicenter efficacy and safety study of the single contraceptive implant Implanon®. Hum. Reprod. 14(4), 976-981 (1999).
73. Funk S, Miller MM, Mishell DR et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 71(5), 319-326 (2005).
74. No authors listed. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative study group on the desogestrel-containing progestogen-only pill. Eur. J. Contracept. Reprod. Health Care 3(4), 169-178 (1998).
75. Yela DA, Monterio IM, Bahamondes LG, del Castillo S, Bahamondes MV, Fernandes A. Weight variation in users of the levonorgesterel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil. Rev. Assoc. Med. Bras. 52(1), 32-36 (2006).
76. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303(3), 235-241 (2010).
77. Yost J, Krainovich-Miller B, Budin W, Norman R. Assessing weight perception accuracy to promote weight loss among U.S female adolescents: a secondary analysis. BMC Public Health 10, 465 (2010).
78. Wane S, van Uffelen JGZ, Brown W. Determinants of weight gain in young women. J. Women's Health 19(7), 1327-1340 (2010).
79. Janssen I, Katzmarzzyk PT, Boyce WF et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationship with physical activity. Obesity Rev. 2, 123-132 (2005).